An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ET1402L1 CART (Primary)
Indications Carcinoma; Hepatic tumours; Hepatoblastoma; Liver cancer
Focus Adverse reactions
Acronyms ARYA-2
Sponsors Eureka Therapeutics

Most Recent Events

02 Apr 2024 According to an Eureka Therapeutics media release, company announced the activation of UCSF Benioff Childrens Hospitals as the first California site to join the ARYA-2 clinical trial.
15 Dec 2022 Planned number of patients changed from 25 to 15.
15 Dec 2022 Planned End Date changed from 28 Feb 2026 to 31 Jan 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight